Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs iShares MSCI United Kingdom (FTSE) (EWU) Price & Performance

Adaptive Biotechnologies CorpTrade
iShares MSCI United Kingdom (FTSE)Trade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs iShares MSCI United Kingdom (FTSE) — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while iShares MSCI United Kingdom (FTSE) trades at $48.32. Which is the better fit depends on your goals.

ADPTEWU
Market Cap
$4.04B
Sector
HealthBroad Market / Factor
52-Week High
$25.45$48.68
52-Week Low
$12.30$40.90
Enterprise Value
$4.10B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.

The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.

iShares MSCI United Kingdom (FTSE)

EWU, the iShares MSCI United Kingdom ETF, trades at $48.33, down 0.33% on the day, with a bullish technical signal driven by moving averages. The ETF tracks UK large-cap equities, with recent institutional activity showing mixed positions. Key support and resistance cluster around $48-$49, while RSI levels indicate neutral momentum. Geopolitical tensions and oil price volatility influence FTSE 100 performance, as highlighted in recent financial news.

The outlook for EWU is cautiously optimistic, supported by technical strength but tempered by macroeconomic risks. Opportunities include exposure to UK market resilience, while risks involve Middle East tensions and inflation concerns. Investors should weigh institutional inflows against broader market volatility for balanced positioning.

Returns comparison

Trailing returns across standard periods

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About iShares MSCI United Kingdom (FTSE)

EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.

Read more on EWU